Stephanie Earnshaw

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Search Publications

Filter

Filter by Year

Search Results

Cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury in the French health care setting

Erratum for Earnshaw et al., "Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom"

Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom

Clinical and economic impacts of large volume delayed sampling and pathogen reduction technology platelet processing strategies in the United States

Costs and outcomes associated with large volume delayed sampling and pathogen reduction technology processing

The cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury

Health and economic impact of routine pediatric pneumococcal immunization crograms in Canada: A retrospective analysis

Economic evaluations of biological treatments for moderate-to-severe Crohn's Disease: Findings from a systematic literature review

The economic burden of Crohn's disease in Europe: Findings from a systematic literature review

Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada"

Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada

Are we ready to use constrained optimization in health outcomes research?

Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. Health plan

Cardiovascular genetic risk testing for targeting statin therapy in the primary prevention of atherosclerotic cardiovascular disease: A cost-effectiveness analysis

Cost-effectiveness of maintaining daily intake of oat β-glucan for coronary heart disease primary prevention

Cardiovascular genetic risk testing for targeting statin therapy in the primary prevention of cardiovascular disease: A cost-effectiveness analysis

Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model

A Methodological Review of US Budget-Impact Models for New Drugs

Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China

Cost-effectiveness of Afatinib versus Erlotinib in the First-line Treatment of Patients with Metastatic Non-small Cell Lung Cancer with EGFR Exon 19 Deletion Mutations